EpimAb Biotherapeutics, a Shanghai bi-specifics company focused on cancer and immunotherapies, closed a $74 million Series B financing. The company uses its FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform to generate bi-specific molecules with antibody-like properties. EpimAb is developing its own portfolio of bi-specifics and licenses its discovery technology to other pharmas. The Series B was co-led by SDIC Fund and Sherpa Healthcare, and included investments from SCVC and other investors. So far, EpimAb has raised a total of more than $100 million.
Source: China Biotoday
